about
sameAs
Exposure to attention deficit hyperactivity disorder medications during pregnancyAdverse events after the use of benznidazole in infants and children with Chagas diseasePopulation pharmacokinetic study of benznidazole in pediatric Chagas disease suggests efficacy despite lower plasma concentrations than in adultsQuality of Reporting and Adherence to ARRIVE Guidelines in Animal Studies for Chagas Disease Preclinical Drug Research: A Systematic ReviewTiming and utility of ultrasound in diarrhea-associated hemolytic uremic syndrome: 7-year experience of a large tertiary care hospital.Safety of gadolinium during pregnancy.Risks of statin use during pregnancy: a systematic review.Methadone exposure during lactation.Use of hypoglycemic drugs during lactation.Maternal-fetal transport of hypoglycaemic drugs.Exposure to alcohol-containing medications during pregnancy.Exposure to sibutramine during pregnancy.When pregnant women are not screened for HIV.Trastuzumab treatment for breast cancer during pregnancy.Pharmaceutical agents and pregnancy in urology practice.Inactive pharmaceutical ingredients : implications for pregnancy.Favorable pregnancy outcome following Trastuzumab (Herceptin) use during pregnancy--Case report and updated literature review.Methamphetamine detection in maternal and neonatal hair: implications for fetal safety.Safety of neuraminidase inhibitors against novel influenza A (H1N1) in pregnant and breastfeeding women.Pharmacologic treatment of hyperthyroidism during lactationPediatric clinical pharmacology studies in Chagas disease: focus on Argentina.Exposure to fifth disease in pregnancy.Pharmacokinetics of disappearance of cocaine from hair after discontinuation of drug use.Sulfonylurea intoxication at a tertiary care paediatric hospital.Predisposition to epilepsy--does the ABCB1 gene play a role?Severe extrapiramidal symptoms after nonintentional risperidone exposure in a child: case report and review of the literature.Use of physostigmine for hallucinogenic plant poisoning in a teenager: case report and review of the literature.The human placental perfusion model: a systematic review and development of a model to predict in vivo transfer of therapeutic drugs.The status of paediatric medicines initiatives around the world--What has happened and what has not?A systematic review of the fetal safety of interferon alpha.Prediction of infant drug exposure through breastfeeding: population PK modeling and simulation of fluoxetine exposure.Pulmonary function of a paediatric cohort of patients with postinfectious bronchiolitis obliterans. A long term follow-up.Case 2: Where did you get that DRESS?Relative bioequivalence of amoxicillin dissolved in breast milk.Prenatal exposure to mycophenolate mofetil: an updated estimate.Sudden-onset tachypnea and confusion in a previously healthy teenager.Unusual reactions to 5-HT3 receptor antagonists in a child with rhabdomyosarcoma.Is use of nifurtimox for the treatment of Chagas disease compatible with breast feeding? A population pharmacokinetics analysis.Authors' response: Long-term lung function in postinfectious bronchiolitis obliterans.Cost of Bordetella pertussis illness in tertiary hospitals in Argentina.
P50
Q24679615-C622B121-1CAD-46FB-91F0-5A8C2FB43C92Q28301421-4ABF65A4-CFE4-4695-8CD5-A476F5AB28F3Q28539049-E7FBC1D1-80B5-4CF1-B06C-F12087466BABQ28551079-7027B268-FB25-499F-ADA4-F61A32B5247BQ33387842-93E24A7E-19EF-4BAE-9D73-B03A9C225818Q34506902-BA464E06-C74E-41F2-8BA9-461F42496A62Q34584493-3D580634-4C4C-474D-91BF-469F34600819Q34601781-903F6D14-B864-4CF4-8EA6-F1941ABFD667Q34606503-5D79D663-F07F-4733-852C-412C5C0500ACQ35089163-64DA0C32-5253-4A49-B37C-700C169C91BBQ35613241-4204CC76-B2DD-40AC-A37C-CFBE84BFCBB6Q35941785-36453D12-CAB3-4CEB-BA0D-AC7418BE8B63Q36440183-937BDA9D-49A2-4976-B412-E05E3922BC0BQ36579981-38965A7C-B1ED-4932-B641-EDE1CB7E09BAQ36673369-902CE3C8-30C2-4304-BB13-8C4E0A227BD2Q36703500-73640FFB-4A97-488C-AA68-9D3BE3BA22EEQ36776419-AB72032E-EAF0-4519-A06D-E930CCB16B77Q37174701-413626A0-B083-46C3-B258-453FC3280AB7Q37247004-D18C2FB0-BE59-4B52-BB5E-D33461DAE7C2Q37303262-D58EF9EF-AECA-4B40-8460-E0B7819F9108Q37363965-CE35807B-B36C-4E66-AB3E-70D7FAD374BFQ37475126-41E90327-2BC8-4428-9AF7-8C7D1CE6AB9EQ37501665-8327402A-11A2-4A65-A288-6ECF9A436489Q37685896-A252E03B-4167-46E5-8965-89CB96626806Q37759057-09086E2D-83AF-4B43-A971-3DECCCA0F3ACQ37764666-77592A86-6015-4D8E-A621-6D26FF507397Q37791347-F22C8AA3-5007-4FC7-B040-42E7F7C81E25Q37874439-BAC65315-670E-42A7-8230-4E1284E3A1A4Q37898039-66F2A725-E2A7-49A8-AFDE-37E957C0DB4EQ37971441-CCDC55B3-BB97-4854-B291-0E2FC5AFC136Q39756442-37FB3359-04D4-42AF-8862-41D9679E0550Q41667099-0AC3A277-5C37-497D-A52E-4498965DC494Q42227300-E84CAB51-ADDB-45F0-AFF4-D071BB718192Q42235820-80F8695B-FC23-476E-ACFB-33B105E20EEFQ42836538-7CC3AF3F-0C94-4136-B567-7F80373C1C05Q42852349-A36232EA-34CE-4F0C-A0E4-0AE249D9CFBFQ43201801-336629EF-C6DC-43C7-973A-194841449BA2Q43233510-58B9FA8C-35FF-43CB-B1F5-BDCDF0C3A8F2Q43538686-ABA80DE9-8841-47FC-B50A-158E76E01C79Q44908826-06030ACD-2171-4B98-8F2F-FD4ACC5C56FA
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Facundo Garcia-Bournissen
@ast
Facundo Garcia-Bournissen
@en
Facundo Garcia-Bournissen
@es
Facundo Garcia-Bournissen
@nl
type
label
Facundo Garcia-Bournissen
@ast
Facundo Garcia-Bournissen
@en
Facundo Garcia-Bournissen
@es
Facundo Garcia-Bournissen
@nl
prefLabel
Facundo Garcia-Bournissen
@ast
Facundo Garcia-Bournissen
@en
Facundo Garcia-Bournissen
@es
Facundo Garcia-Bournissen
@nl
P106
P1153
13003928900
P21
P31
P3946
P496
0000-0002-8732-247X